References
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354
Jehle T, Bauer J, Blauth E, Hummel A, Darstein M, Freiman TM, Feuerstein TJ (2000) Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol 130:1227–1234
Krystal JH, D'Souza DC, Belger A, Anand A, Charney DS, Aghajanian GK, Moghaddam B (1999) Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 22:S143–S157
Krystal JH, Sanacora G, Blumberg H, Anand, A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF (2002) Glutamate and GABA systems as targets for novel antidepressant and mood stabilizing treatments. Mol Psychiatry (in press)
Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76–87
Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096–1103
Stefani A, Spadoni F, Bernardi G (1997) Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147:115–122
Urbani A, Belluzzi O (2000) Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 12:3567–3574
Acknowledgements
The authors would like to thank the Clinical Staff of the Clinical Neuroscience Research Unit of the Connecticut Mental Health Center, New Haven, Conn., USA for their contributions to the clinical management of the patient in this report. The authors would like to acknowledge the State of Connecticut for its support of the Abraham Ribicoff Research Facilities, the National Institute of Alcohol Abuse and Alcoholism (KO2 AA 00261-01), the Department of Veterans Affairs through its support of the Alcohol Research Center and National Center for PTSD, and NARSAD Independent Investigation Award (RTM).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coric, V., Milanovic, S., Wasylink, S. et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology 167, 219–220 (2003). https://doi.org/10.1007/s00213-003-1396-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1396-z